What happened
Orakl Oncology announced a $34 million Series A financing round co‑led by Norrsken VC and Singular. The capital will fund expansion of its AI platform that integrates patient‑derived tumor samples, clinical data, and experimental biology, as well as the establishment of new research teams in the United States and United Kingdom and the growth of its international hospital partnership network.
Orakl Oncology, founded in 2023 by Diane‑Laure Pagès, Fanny Jaulin, Ph.D., and Gustave Ronteix, disclosed that it has raised $34 million in a Series A round. The round was co‑led by Norrsken VC and Singular, with participation from existing investors and new backers identified by Pagès as Agate S. Freimane and Jeremy Uzan.
The funding will be allocated to several strategic priorities: expanding the company’s scientific and engineering workforce (now over 40 staff, roughly 30 % of whom hold Ph.D. degrees), establishing new research teams in the United States and United Kingdom, and scaling the company’s AI platform that combines patient‑derived tumor samples, clinical information, and experimental biological data.
Orakl’s platform generates up to 200 GB of multimodal data per patient across seven matched data modalities, creating a proprietary that it believes is more biologically relevant than publicly available cancer datasets. The company has signed five hospital partnerships in 2026 and expects more than 15 additional cancer centers across Europe, North America, and Asia to join its network.
While the technology is positioned for early‑stage oncology drug development, Pagès clarified on LinkedIn that the platform is not yet ready for individualized clinical use. The company’s current focus is on helping researchers identify promising therapeutic candidates and understand tumor‑treatment relationships before clinical trials.
Why it matters
The infusion of $34 million underscores growing investor confidence in AI‑augmented drug discovery, a sector where data quality and biological relevance are critical bottlenecks. Orakl’s approach—building proprietary, multimodal tumor datasets and training AI models on that data—aims to improve the predictability of cancer drug responses, potentially accelerating early‑stage oncology research and reducing costly late‑stage failures. By expanding its hospital network across Europe, North America, and Asia, the company can access a broader spectrum of tumor biology, strengthening its data foundation and making its platform harder for competitors to replicate. While the technology is not yet ready for clinical decision‑making, its focus on pre‑clinical drug development could help pharmaceutical firms prioritize promising candidates more efficiently, ultimately impacting the of new cancer therapies.
Investor interest in AI‑driven drug discovery reflects a broader industry trend toward data‑centric approaches that aim to reduce the high attrition rates in oncology pipelines. By integrating high‑resolution biological data with AI, Orakl seeks to generate more accurate predictive models, which could shorten discovery timelines and lower R&D costs.
The creation of a proprietary, multimodal tumor addresses a key limitation of many AI oncology projects that rely on limited or publicly available data, which may not capture the full heterogeneity of patient tumors. This data advantage could translate into more reliable insights for pharmaceutical partners.
Orakl’s international hospital network not only expands the diversity of its data but also establishes a collaborative ecosystem that can accelerate validation studies and potentially streamline regulatory pathways for future clinical applications.
The Series A size ($34 million) is notable for a pre‑clinical biotech focused on AI, indicating that venture capital firms see tangible commercial potential in the company’s hybrid biology‑AI model, despite the technology still being in the research phase.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
Which component of an AI application is the machine-learning model itself?
What to watch next
Future milestones include the onboarding of additional hospital partners, the release of results demonstrating the AI platform’s predictive performance, and any partnership or licensing agreements with pharmaceutical companies seeking to use Orakl’s data and models for drug development.
Progress on onboarding the projected 15+ new cancer centers and the volume of new tumor data generated, which will be a key indicator of the platform’s scalability.
Publication of validation studies or peer‑reviewed results that the AI model’s predictive accuracy against existing methods.
Announcements of collaborations or licensing deals with pharmaceutical companies, which would signal market adoption of Orakl’s platform for drug candidate selection.
Regulatory or ethical considerations related to the handling of patient‑derived data across multiple jurisdictions, especially as the network expands globally.